Opinion
Video
Managing Adverse Events With Different TKIs
Author(s):
Experts discuss how they approach managing adverse events with tyrosine kinase inhibitors (TKIs) like ripretinib, sunitinib, and regorafenib, highlighting notable differences in their safety profiles and how these differences influence treatment decisions.
Video content above is prompted by the following:
- Beyond efficacy considerations, how do you approach managing adverse events with TKIs like ripretinib, sunitinib, and regorafenib? Are there notable differences in their safety profiles that influence your treatment decisions?
Latest CME
View All
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
May 13th 2025 - Jun 18th 2025
online-activity
Video
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
May 9th 2025 - Jun 14th 2025
online-activity
Video
Proactive Adverse Event Management for HER2+ BTC Treatments
May 8th 2025 - May 9th 2026
online-activity
Related Content
.jpg?fit=crop&auto=format)
